Jefferies analyst Michael Yee upgraded Aligos Therapeutics to Buy from Hold with a price target of $3, up from $2.50.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALGS:
- Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009
- Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
- Aligos Therapeutics initiates dosing in ALG-125755 trial
- Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
- Aligos presents nonclinical data for coronavirus therapeutic program